The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.
George Somlo
No relevant relationships to disclose
Paul Henry Frankel
No relevant relationships to disclose
Thehang H. Luu
No relevant relationships to disclose
Cynthia Ma
No relevant relationships to disclose
Banu Arun
No relevant relationships to disclose
Agustin Garcia
No relevant relationships to disclose
Tessa Cigler
No relevant relationships to disclose
Leah Cream
No relevant relationships to disclose
Harold A. Harvey
No relevant relationships to disclose
Joseph A. Sparano
No relevant relationships to disclose
Rita Nanda
No relevant relationships to disclose
Helen K. Chew
No relevant relationships to disclose
Timothy Jerome Moynihan
No relevant relationships to disclose
Linda T. Vahdat
No relevant relationships to disclose
Matthew P. Goetz
No relevant relationships to disclose
Arti Hurria
Consultant or Advisory Role - GTx; Seattle Genetics
Research Funding - Celgene; GlaxoSmithKline
Joanne E. Mortimer
No relevant relationships to disclose
David R. Gandara
No relevant relationships to disclose
Alice Chen
No relevant relationships to disclose
Jeffrey N. Weitzel
No relevant relationships to disclose